Table 2.
Characteristic | Absolute LS, %-units | Absolute GCS, %-units | GRS, %-units | e’ velocity, cm/s | SRE, 1/s | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
β | SE | P-value | β | SE | P-value | β | SE | P-value | β | SE | P-value | β | SE | P-value | |
Age, per 10 y increase | −0.04 | 0.08 | 0.65 | 0.34 | 0.12 | 0.01 | 1.26 | 0.29 | <0.0001 | −0.51 | 0.03 | <0.0001 | −0.07 | 0.01 | <0.0001 |
Female sex | −1.42 | 0.21 | <0.0001 | −1.21 | 0.32 | 0.0002 | −0.62 | 0.76 | 0.42 | 0.09 | 0.10 | 0.34 | −0.05 | 0.02 | 0.01 |
Hypertension | −0.88 | 0.21 | <0.0001 | 0.31 | 0.32 | 0.34 | 0.43 | 0.76 | 0.57 | −0.94 | 0.09 | <0.0001 | −0.14 | 0.02 | <0.0001 |
SBP, per 10 mm Hg increase | −0.17 | 0.05 | 0.0008 | −0.11 | 0.08 | 0.14 | −0.11 | 0.18 | 0.55 | −0.14 | 0.02 | <0.0001 | −0.03 | 0.00 | <0.0001 |
DBP, per 10 mm Hg increase | −0.49 | 0.09 | <0.0001 | −0.37 | 0.14 | 0.01 | 0.05 | 0.33 | 0.87 | −0.20 | 0.04 | <0.0001 | −0.04 | 0.01 | <0.0001 |
Antihypertensive medication use | −0.64 | 0.21 | 0.003 | 0.41 | 0.31 | 0.20 | 0.70 | 0.75 | 0.34 | −0.84 | 0.09 | 0.0001 | −0.13 | 0.02 | <0.0001 |
BMI, per 5 kg/m2 increase | −0.05 | 0.07 | 0.52 | −0.04 | 0.10 | 0.72 | −0.34 | 0.24 | 0.16 | −0.03 | 0.03 | 0.36 | 0.00 | 0.01 | 0.58 |
Smoking | −0.50 | 0.21 | 0.02 | −0.05 | 0.31 | 0.86 | 0.80 | 0.73 | 0.27 | −0.28 | 0.09 | 0.003 | −0.07 | 0.02 | <0.0001 |
Fasting glucose, per 10 mg/dl increase | −0.06 | 0.02 | 0.01 | −0.02 | 0.03 | 0.58 | −0.06 | 0.08 | 0.42 | −0.06 | 0.01 | <0.0001 | −0.01 | 0.00 | 0.01 |
LVMI, per 10 g/m2 increase | −0.23 | 0.05 | <0.0001 | −0.16 | 0.08 | 0.05 | 0.08 | 0.19 | 0.69 | −0.14 | 0.02 | <0.0001 | −0.03 | 0.00 | <0.0001 |
LVEF, per 5% decrease | −0.34 | 0.09 | 0.0003 | −0.72 | 0.14 | <0.0001 | −0.23 | 0.33 | 0.49 | 0.08 | 0.04 | 0.07 | −0.01 | 0.01 | 0.37 |
Adjusted for speckle-tracking analyst, study site, image quality, and familial relatedness